Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Zellweger

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Praxis|September 21, 2005
[How to treat a localized prostate cancer: irradiation, surgery or watchful waiting?]T Zellweger, T Gasser
Lancet (London, England)|April 13, 1996
Randomised trials in German-language journalsM Egger, T Zellweger, G Antes
Revue Medicale Suisse|December 21, 2013
[Renal masses and indication to nephrectomy: preoperative assessment and clinical presentation of five cases]M Vedana, S Geisler, T Zellweger, et al.
JAMA|December 18, 1996
The CONSORT statementC Junker, M Egger, M Schneider, et al.
International Journal of Cancer|March 29, 2001
Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor modelS Leung, H Miyake, T Zellweger, et al.
Lancet (London, England)|August 2, 1997
Language bias in randomised controlled trials published in English and GermanM Egger, T Zellweger-Zähner, M Schneider, et al.
Molecular Urology|November 3, 2001
Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cellsH Miyake, S Hara, T Zellweger, et al.
Neoplasia (New York, N.Y.)|September 26, 2001
Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterinT Zellweger, H Miyake, L V July, et al.
Urology|August 15, 2001
Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancerM E Gleave, H Miyake, T Zellweger, et al.
BJU International|August 22, 2003
Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour modelT Zellweger, S Kiyama, K Chi, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Praxis|September 21, 2005
[How to treat a localized prostate cancer: irradiation, surgery or watchful waiting?]T Zellweger, T Gasser
Lancet (London, England)|April 13, 1996
Randomised trials in German-language journalsM Egger, T Zellweger, G Antes
Revue Medicale Suisse|December 21, 2013
[Renal masses and indication to nephrectomy: preoperative assessment and clinical presentation of five cases]M Vedana, S Geisler, T Zellweger, et al.
JAMA|December 18, 1996
The CONSORT statementC Junker, M Egger, M Schneider, et al.
International Journal of Cancer|March 29, 2001
Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor modelS Leung, H Miyake, T Zellweger, et al.
Lancet (London, England)|August 2, 1997
Language bias in randomised controlled trials published in English and GermanM Egger, T Zellweger-Zähner, M Schneider, et al.
Molecular Urology|November 3, 2001
Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cellsH Miyake, S Hara, T Zellweger, et al.
Neoplasia (New York, N.Y.)|September 26, 2001
Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterinT Zellweger, H Miyake, L V July, et al.
Urology|August 15, 2001
Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancerM E Gleave, H Miyake, T Zellweger, et al.
BJU International|August 22, 2003
Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour modelT Zellweger, S Kiyama, K Chi, et al.
Pageof 2